Option Care Health’s (OPCH) “Outperform” Rating Reiterated at Barrington Research

Option Care Health (NASDAQ:OPCH)‘s stock had its “outperform” rating reiterated by Barrington Research in a report released on Wednesday, Benzinga reports. They presently have a $38.00 target price on the stock. Barrington Research’s price target would indicate a potential upside of 29.74% from the company’s previous close. Barrington Research also issued estimates for Option Care Health’s Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group upped their price target on Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, March 4th.

Option Care Health Stock Down 2.1 %

OPCH opened at $29.29 on Wednesday. The business has a 50 day moving average of $32.04 and a 200-day moving average of $31.50. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of 19.27, a P/E/G ratio of 1.65 and a beta of 1.22. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. Option Care Health has a 1-year low of $24.23 and a 1-year high of $35.74.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the business posted $0.21 EPS. The business’s quarterly revenue was up 12.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Option Care Health will post 1.17 earnings per share for the current year.

Insider Activity

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was purchased at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the completion of the transaction, the director now directly owns 269,528 shares of the company’s stock, valued at approximately $8,503,608.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.64% of the stock is owned by company insiders.

Institutional Trading of Option Care Health

Large investors have recently bought and sold shares of the stock. Principal Securities Inc. acquired a new stake in shares of Option Care Health in the 4th quarter valued at $27,000. Parallel Advisors LLC lifted its holdings in Option Care Health by 130.2% during the 4th quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock valued at $28,000 after purchasing an additional 478 shares during the last quarter. TFO Wealth Partners LLC boosted its position in Option Care Health by 24,625.0% in the fourth quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock valued at $33,000 after buying an additional 985 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in Option Care Health during the third quarter worth about $37,000. Finally, Park Place Capital Corp increased its holdings in shares of Option Care Health by 48.4% during the first quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after buying an additional 372 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.